AusDiagnostics Pty Ltd is the major supplier of Highly Multiplexed molecular diagnostics in Australia with offices also in London, Dallas and Auckland. Kits falling into twelve kinds of IVD are listed in the Australian Register of Therapeutic goods and the company operates a quality management system to comply with ISO 13485.
AusDiagnostics has always prided itself on offering the best quality kits on the market for the most competitive price. Providing a better clinical outcome for patients is a major driver of company policy.
Keith Stanley, Managing Director, was educated at Cambridge University, being awarded his PhD in Natural Sciences. Following nine years at the European Molecular Biology Laboratory he moved to Australia where he held a professorial position at the University of New South Wales while working at the Centre for Immunology. A collaboration with Corbett Research resulted in a START grant in 2004 and the launching of AusDiagnostics in 2006.
Richard Hale, Chief Operating Officer AusDiagnostics UK. Following completion of a PhD at Cambridge University in Biochemistry, Richard worked with R & D at Glaxo on natural products and recombinant protein expression. He was part of a team that managed a technology spin-out to the biotech sector, and was COO at Cellzome until its ultimate acquisition by GSK in 2012. Richard was recruited to establish the UK branch of AusDiagnostics in 2013.
Alan Jernigan, Chief Operating Officer AusDiagnostics USA, has 20 years as a sales and operations leader for a variety of medical, pharmaceutical and biotech companies both on the human and veterinary side. He has launched a number of products which have improved lives and helped healthcare providers do their jobs better.
Mila Al-Halbouni, Business Manager of the New Zealand branch, has a PhD in Biotechnology from the University of Aachen in Germany and over 7 years sales and marketing experience.